Treatment of postherpetic neuralgia: focus on pregabalin
Author(s) -
Kimberly A. Cappuzzo
Publication year - 2008
Publication title -
clinical interventions in aging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.184
H-Index - 76
eISSN - 1178-1998
pISSN - 1176-9092
DOI - 10.2147/cia.s3386
Subject(s) - pregabalin , medicine , postherpetic neuralgia , gabapentin , neuralgia , neuropathic pain , dermatology , anesthesia , alternative medicine , pathology
Postherpetic neuralgia (PHN) is a devastating, chronic pain syndrome that can develop following an outbreak of herpes zoster and becomes increasingly common as patients age. PHN can be difficult to treat and often requires trials of multiple agents to achieve significant pain relief. Pregabalin is the newest agent to gain approval for PHN. Data suggest efficacy for relief of pain and sleep disturbance secondary to PHN in affected patients. Although there are no head-to-head comparisons, pregabalin appears comparable to gabapentin and other first-line agents for treating PHN.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom